Welcome to LookChem.com Sign In|Join Free

CAS

  • or

925438-48-8

Post Buying Request

925438-48-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

925438-48-8 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 925438-48-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,2,5,4,3 and 8 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 925438-48:
(8*9)+(7*2)+(6*5)+(5*4)+(4*3)+(3*8)+(2*4)+(1*8)=188
188 % 10 = 8
So 925438-48-8 is a valid CAS Registry Number.

925438-48-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name 3-chloromethyl-6-(2-nitro-phenyl)-imidazo[2,1-b]thiazole

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:925438-48-8 SDS

925438-48-8Relevant articles and documents

The identification of the SIRT1 activator SRT2104 as a clinical candidate

Ng, Pui Yee,Bemis, Jean E.,Disch, Jeremy S.,Vu, Chi B.,Oalmann, Christopher J.,Lynch, Amy V.,Carney, David P.,Riera, Thomas V.,Song, Jeffrey,Smith, Jesse J.,Lavu, Siva,Tornblom, Angela,Duncan, Meghan,Yeager, Marie,Kriksciukaite, Kristina,Gupta, Akanksha,Suri, Vipin,Elliot, Peter J.,Milne, Jill C.,Nunes, Joseph J.,Jirousek, Michael R.,Vlasuk, George P.,Ellis, James L.,Perni, Robert B.

, p. 793 - 797 (2013/12/04)

We have identified SRT2104 (4) as the first direct synthetic SIRT1 activator clinical candidate. The compound was derived from the optimization of a previously described imidazo[1,2-b]thiazole scaffold. SRT2104 was selected as a development candidate based on a combination of biochemical activity and pharmacokinetic profile. The in vivo characteristics of SRT2104 were superior to those of analogues with similar activation profiles. The overall preclinical profile suggests that the compound has potential to provide therapeutic benefit in a clinical setting. 2013 Bentham Science Publishers.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 925438-48-8